Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MIST
MILESTONE PHARMACEUTICALS INC.
NASDAQ
$1.16
▼ DOWN 2.52% (-0.03)

KEY STATISTICS

Market Cap$144.42 M
52w High$3.06
52w Low$1.00
Dividend Yield—
Frequency—
P/E-1.71
Volume865.29K
Shares Out.124.50M

COMPANY

LEADERSHIP

Joseph G. Oliveto
CHIEF EXECUTIVE
Joseph G. Oliveto

COMPENSATION 2026

Salary$649,641
Stock Awards$538,128
Incentive Plan Pay$250,112
All Other Comp.$31,631
Total$2,121,015

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 9, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
38

PRICE TARGET

Target High$6.00
Target Low$3.00
Target Median$4.50
Target Consensus$4.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$1.14M
NOV
11
WED

PRICE

$1.16 ▼ DOWN 2.52% (−$0.03)
$1.14$1.16$1.18$1.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.16

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com ↗

Milestone Pharmaceuticals Inc. is a Montréal-based biopharma developing cardiovascular medicines, including etripamil for arrhythmias, with ongoing Phase III and II trials and collaborations with Ji Xing Pharmaceuticals.

INDUSTRY

Biotechnology

A PRODUCT MILESTONE PHARMACEUTICALS INC. IS KNOWN FOR

CARDAMYST™ (etripamil) nasal spray
CARDAMYST™ (etripamil) nasal spray

CARDAMYST™ is an FDA-approved, self-administered nasal spray for at-home treatment of PSVT, marking Milestone Pharmaceuticals' first commercial product and a major advancement in patient-controlled heart rhythm management.

COMPETITORS

COMPETITOR
ABT COMPARE
BMY COMPARE
JNJ COMPARE
PFE COMPARE
SNY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
SURI
4.47% · 3.3M
GWX
0.00% · 22.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
33.98%
HOLDERS
108
TOP 12 OF 108 · RANKED BY POSITION SIZE
Adage Capital Partners Gp, L.L.C.
7.0M sh · $13.95M
Rtw Investments, LP
6.3M sh · $7.53M
Propel Bio Management, LLC
5.1M sh · $10.25M
Blackrock Inc.
5.0M sh · $6.56M
Orbimed Advisors LLC
3.2M sh · $6.44M
Morgan Stanley
3.0M sh · $5.94M
Simplify Asset Management Inc.
2.8M sh · $5.67M
Two Sigma Investments, LP
2.3M sh · $2.76M
Vhcp Management Iii, LLC
2.1M sh · $33.09M
Goldman Sachs Group Inc
2.0M sh · $2.38M
Marshall Wace, Llp
1.9M sh · $2.31M
Millennium Management LLC
1.5M sh · $1.84M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Giles Lisa M.
Purchase · 77.0K shares
2026-06-10
★
DIRECTOR
Fischer Seth H. Z.
Purchase · 77.0K shares
2026-06-10
★
DIRECTOR
Duty Stuart
Purchase · 77.0K shares
2026-06-10
★
DIRECTOR
Wills Robert James
Purchase · 77.0K shares
2026-06-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
3 GRADES IN THE LAST 12 MONTHS
Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY TD Cowen BUY

SECTORS PEERS

PEERPRICE
PEPG$3.08COMPARE
IPHA$2.22COMPARE
CRBP$10.91COMPARE
MOLN$4.50COMPARE
CRDF$0.94COMPARE
RANI$0.84COMPARE
ELTX$2.84COMPARE